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Abstract
Nicotine is so desirable to many people that when they are given only the options of consuming
nicotine by smoking, with its high health costs, and not consuming nicotine at all, many opt for the
former. Few smokers realize that there is a third choice: non-combustion nicotine sources, such
as smokeless tobacco, electronic cigarettes, or pharmaceutical nicotine, which eliminate almost all
the risk while still allowing consumption of nicotine. Widespread dissemination of misleading health
claims is used to prevent smokers from learning about this lifesaving option, and to discourage
opinion leaders from telling smokers the truth. One common misleading claim is a risk-risk
comparison that has not before been quantified: A smoker who would have eventually quit nicotine
entirely, but learns the truth about low-risk alternatives, might switch to an alternative instead of
quitting entirely, and thus might suffer a net increase in health risk. While this has mathematical face
validity, a simple calculation of the tradeoff -- switching to lifelong low-risk nicotine use versus
continuing to smoke until quitting -- shows that such net health costs are extremely unlikely and
of trivial maximum magnitude. In particular, for the average smoker, smoking for just one more
month before quitting causes greater health risk than switching to a low-risk nicotine source and
never quitting it. Thus, discouraging a smoker, even one who would have quit entirely, from
switching to a low-risk alternative is almost certainly more likely to kill him than it is to save him.
Similarly, a strategy of waiting for better anti-smoking tools to be developed, rather than
encouraging immediate tobacco harm reduction using current options, kills more smokers every
month than it could possibly ever save.
Introduction
Tobacco harm reduction (THR), the substitution of low-
risk nicotine products for cigarette smoking, is increas-
ingly recognized as offering huge public health benefits.
Smoking is well known to be a very hazardous activity,
but the main reason why people smoke - nicotine - does
not itself cause much risk when separated from inhaling
smoke. Extensive epidemiology shows that the use of
Western oral smokeless tobacco (ST) causes a trivial frac-
tion of the mortality risk from smoking, and it is believed
that electronic cigarettes and pharmaceutical nicotine
products (gums, patches, lozenges) have similarly low
risks. Many smokers will keep smoking until they die from
it because, when given only the options of smoking or
completely giving up nicotine, many will not give it up.
But many of them probably could be persuaded to switch
to a low-risk source of nicotine, and the health benefits
would be almost as good as quitting entirely.
Published: 3 November 2009
Harm Reduction Journal 2009, 6:29 doi:10.1186/1477-7517-6-29
Received: 2 July 2009
Accepted: 3 November 2009
This article is available from: http://www.harmreductionjournal.com/content/6/1/29
© 2009 Phillips; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Harm Reduction Journal 2009, 6:29 http://www.harmreductionjournal.com/content/6/1/29
Page 2 of 10
(page number not for citation purposes)
Readers interested in background on THR that is beyond
the present scope, including quantifications of its poten-
tial benefits and reports of past successes, can find them in
our website [1], in various overview papers (Phillips CV,
Heavner K, Bergen P. Tobacco - the greatest untapped
potential for harm reduction. Submitted, Available at:
http://www.tobaccoharmreduction.org/wpapers/
006.htm) [2,3], and in endorsements by British and
American medical organizations [4,5]. Other relevant
contributions to the issue include studies that allow esti-
mates of the potential benefits (Geertsema K, Phillips CV,
Heavner K. University Student Smokers' Perceptions of
Risks and Barriers to Harm Reduction, Submitted, Availa-
ble at: http://tobaccoharmreduction.org/wpapers/
001.htm) [6,7], estimates of how much THR has already
been employed in the past in the U.S. [8], and how it has
largely succeeded in Sweden, where ST has substantially
replaced smoking, resulting in the lowest tobacco-related
disease rates in the Western world [9,10].
Stated estimates for how much less risky ST is compared
to smoking vary somewhat, but the actual calculations put
the reduction in the range of 99% (give or take 1%),
putting the risk down in the range of everyday exposures
(such as eating french fries or recreational driving), that
provoke limited public health concern [6]. Even this low
risk is premised on the unproven assumption that nico-
tine causes small but measurable cardiovascular disease
risk (as do most mild stimulants such as decongestant
medicines, energy drinks, and coffee), since such risks
account for almost all of the remaining 1%. Perhaps just
as important, even a worst-case scenario puts the risk
reduction at about 95%, meaning that any scientifically
plausible estimate shows THR has huge potential health
benefits. There is no epidemiology for the new electronic
cigarettes and very little useful epidemiology for assessing
long term use of pharmaceutical nicotine products. But
since most of the apparent risk from ST comes from nico-
tine, and the other ingredients in the non-tobacco prod-
ucts are believed to be quite benign, we can conclude that
the risks across these product categories are functionally
identical from the perspective of THR.
Because it is not necessary to distinguish among product
categories for purposes of the present analysis, a collective
description,  THR products, is used. Product preferences
vary and many smokers become attached to aspects of the
smoking experience, including the aesthetics (flavor,
smell, mouth and airway feel) and social behaviors for
which no other product is a perfect substitute. The variety
of THR products increases the chance that a given smoker
will find one of them a sufficiently good substitute for
smoking.
Harm reduction is a generally accepted public health prin-
ciple that recognizes that eliminating an exposure is often
not practical, welfare maximizing, or ethical, and so we
should endeavor to reduce the harm from the exposure.
The best example is encouraging the use of seatbelts with-
out trying to curtail exposure to automotive transport.
However, for politically controversial exposures (e.g.,
injection drug use, sexual activity outside of marriage,
tobacco use) opponents of harm reduction often try to
defend their beliefs that "just say no" (abstinence only) is
the only acceptable option by observing that "lower risk
does not mean no risk". But in the absence of quantifica-
tion, this observation is merely a trivial vocabulary lesson,
not a useful contribution to decision making. The present
analysis offers a quantification that illustrates how a 99%
reduction in risk is so close to zero risk that the "let's wait
and see if we can do even better than current low-risk
options" attitude is clearly killing more people than it
could ever save. Rational decision strategies call for taking
advantage of existing knowledge at some point, rather
than continuing to search. If a risk is low enough, it is
obviously better to accept that risk than to stick with high
risk levels hoping that a way to achieve even lower risk
will be discovered.
Harm reduction is particularly compelling for the use of
nicotine because so many people have such a strong pro-
pensity for using it. Nicotine is a very beneficial drug for
many people, providing alertness, focus, pleasure, and
relief from a variety of psychological symptoms and
pathologies. A substantial fraction of the population gets
these benefits by smoking even though the health costs
are so high, which means that demanding they quit
entirely entails great welfare costs and is not likely to
work.
Smoking can be described compellingly in terms of nor-
mal welfare economics, such that the consumer is maxi-
mizing his welfare by choosing among the available
options (smoke or not smoke). Both choices have costs
and benefits, and some consumers judge that the benefits
of smoking outweigh its very high costs. However, for
many such smokers, the possible reduction in benefits
from switching to a less-enjoyed product would be greatly
outweighed by the reduction in costs from health risks, so
knowing about the benefits of switching to a THR product
would be tremendously beneficial. Alternatively, it is
often implicitly argued that smoking behavior does not
conform to rational choice theory: Smokers do not choose
smoking from among their options, but rather "addic-
tion" (a rather slippery concept which is seldom actually
defined, but is still widely invoked and accepted) or some
related phenomenon prevents smokers from being able to
choose to be abstinent. In that case, THR offers a health
benefit that is not going to be achieved by choosing absti-
nence, and thereby also provides a great welfare benefit.
Thus, either of these models of individual behavior leads
to the same conclusion: Many people who are faced withHarm Reduction Journal 2009, 6:29 http://www.harmreductionjournal.com/content/6/1/29
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the dichotomous choice of smoking and abstinence will
not just quit, and many of them would be better off using
nicotine in a low-risk form. Therefore, whether one
believes that smokers are making a rational welfare-maxi-
mizing choice or are victims of a curse, THR makes sense
from the perspective of both individual welfare and pub-
lic health. (Further exploration of the policy-ethics argu-
ments surrounding promotion of THR can be found in
the collection of papers at http://www.tobaccoharmre
duction.org/wpapers/010.htm.)
It might seem surprising that something as promising as
THR is largely unknown and unimplemented as a policy.
Much of the problem is that people (smokers, health edu-
cators, policy makers) hear the messages that THR prod-
ucts are not safe, that "all tobacco is deadly", and "the
only safe choice is to quit entirely". This convinces people
that THR either is not possible at all or represents only a
marginal improvement that is not worth pursuing. Still,
this begs the question of why anyone would choose to
deliver the message that a 99% reduction in risk is almost
as bad as continuing to smoke, rather than the obviously
more accurate message that it is almost as good as quitting
entirely. Answering this is useful for understanding the
significance of the analysis presented here.
Why analyses like this one are needed
The discourse surrounding tobacco policy and education
is dominated by people who pursue the most extreme
possible goal regarding tobacco: unconditional elimina-
tion of its use. Explicit statements of that goal are very
common. Their goal is not to design tobacco policies that
maximize human welfare or even that maximally reduce
physical health costs. Any such concerns are, at best, sec-
ondary to the goal of simply reducing consumption of all
forms of tobacco, and usually also reducing any long-term
self-administration of nicotine that has been extracted
from the tobacco (i.e., electronic cigarettes and pharma-
ceutical products). Thus, while getting smokers to switch
to using ST represents an almost perfect success from the
public health perspective (and is even more attractive
from the human welfare perspective), it represents little or
no progress for someone pursuing the goal of uncondi-
tionally eliminating tobacco use from the world. Presum-
ably those who believe that eliminating tobacco is the
appropriate goal would not dispute this. With this in
mind, it is much easier to understand why some people
reject a 99% reduction in risk as not worth pursuing:
reducing risk is not the major factor in their objective
function.
(This, of course, does not address the question of why anti-
tobacco extremists are motivated to pursue this goal.
Exploring possible explanations is beyond present scope
(they are discussed in a bit more depth in Phillips,
Heavner & Bergen (Phillips CV, Heavner K, Bergen P.
Tobacco - the greatest untapped potential for harm reduc-
tion. Submitted, Available at: http://www.tobaccoharmre
duction.org/wpapers/006.htm)). The list includes: the
economically absurd belief that nicotine products provide
no benefits and thus no one really wants to use them, usu-
ally closely tied to the paternalistic notion that the activ-
ists are better able to determine what people really want
than the consumers themselves; an irrational hatred of
companies who make nicotine products (often with the
exception of pharmaceutical companies who many anti-
tobacco activists are closely allied with); the common
drug-war mentality of wanting to purify everyone and
considering users to be sinners; and simple involvement
of individual ego, whereby the goals becomes about win-
ning the race and defeating the opponent, without ever
admitting that their strategy may not have been optimal,
rather than trying to develop humane, rational, practical
policies.)
Understanding this is critical because those pursuing the
extreme anti-tobacco agenda are often thought to have
risk reduction as their primary objective, and take advan-
tage of this by making dozens of health risk claims. It is,
of course, people's right to hold the political opinion that
we should work toward eliminating all tobacco use,
regardless of how pursuing that goal would affect people's
welfare and health, and it is those advocates' right to cam-
paign for their goal. The ethical problems and public con-
fusion result when the primary goal is eliminating
tobacco, but the rhetoric mostly consists of claims about
health. When such a disconnect occurs, the claims are
merely rationalizations or attempts to persuade those
who might not be persuaded by the true goal, rather than
representing true underlying motives. When the language
of science is used to rationalize rather than analyze, the
probability is high that the science will degenerate into
pseudo-scientific rhetoric.
None of this should come as a great surprise given the his-
tory of other abstinence-only agendas presented in the
guise of public health. It has long been accepted by the
public health community that harm reduction strategies
for illicit drug use, from needle exchanges to education
about the advantages of moderation, save many lives.
Nevertheless, anti-drug warriors who support a "just say
no"-only strategy frequently try to shut down programs
that promote harm reduction. Their explicit argument is
never "those criminals deserve to die if they do not quit
using drugs, so we should not try to lower their risk"; in
fact, their public argument is often based on inaccurate
claims that the harm reduction strategies increase risk.
Similarly, it has been known for decades that abstinence-
only approaches to sex education in the West produce
inferior health outcomes compared to balanced harm-Harm Reduction Journal 2009, 6:29 http://www.harmreductionjournal.com/content/6/1/29
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reduction-oriented education, combined with product
and service provision. Activists who persist in claiming
that promoting only sexual abstinence is health-improv-
ing seem to not be concerned with health so much as they
are just annoyed that people are enjoying sex outside of
marriage.
The politics and rhetoric of the abstinence-only approach
to nicotine use have much in common with these other
abstinence-only approaches, but this is not yet widely rec-
ognized. As a result, many people who are genuinely
motivated by promoting personal and public health, and
do not share the extreme anti-tobacco agenda, often
believe the inaccurate health claims that are really ration-
alizations for the anti-tobacco position. Since this often is
to the detriment of both public health and the scientific
legitimacy of the health sciences, it is important for the
public health and scientific communities to debunk these
claims.
Debunking these claims is a difficult challenge. Anti-THR
health claims are typically speculation or assertion, with-
out the support of evidence or analysis, and thus actual
scientists will immediately relegate them to the realm of,
at best, speculative hypothesis. But it is easy to take advan-
tage of laypeople's tendencies to accept at face value all
manner of urban myths and other misconceptions, and to
demand scientific proof that the claim is wrong [11].
Endeavoring to disprove a long list of assertions is far
more difficult than making up those claims in the first
place. Indeed, the sheer number and ever-changing nature
of those claims is further evidence of attempts to rational-
ize a pre-determined conclusion, not an exploration of
real reasons: Generally when someone shops different
claims to various populations to see which changes their
behavior in the preferred way, we call it marketing, not
science, education, or ethical public health policy.
Methods of responding to misleading claims
But though trying to disprove unsubstantiated claims is
not considered necessary in scientific thinking and is obvi-
ously an epistemic nightmare, it is necessary to advance
public health policy. Advocates of THR have endeavored
to debunk some of the most erroneous anti-THR claims.
Some claims have been debunked by simply pointing to
existing scientific literature (e.g., claims that ST use causes
substantial disease risk are contradicted by decades of epi-
demiologic evidence to the contrary). Some claims have
required new directed empirical work (e.g., the claim that
promoting THR would create a "gateway" to smoking
required focused empirical research and analysis to
debunk). Still others are hypothetical scenarios that
require an analytic approach to show they are misleading
or of minor consequence.
An example of such analysis is the debunking of the claim
that if we allow smokers to learn that they have low-risk
alternative sources of nicotine, then many people who
might have had zero risk from consuming nicotine
(because they would have quit entirely or not started) will
choose to consume ST or pharmaceutical nicotine and
suffer some small risk. This will, the claim goes, increase
total population risk. But when it is demonstrated that net
social risk could not conceivably increase in this manner,
anti-THR activists sometimes counter with a second asser-
tion: Even though total population risk will decrease,
there are many smokers who would have quit nicotine
entirely but instead switch to a low-risk product, and they
will suffer greater risks than they otherwise would, and
that this constitutes an argument against THR. Debunking
this requires the additional analysis presented below.
One might argue that the ethical considerations make
quantifying this claim irrelevant. The leading deontologi-
cal tenet of modern health ethics is the obligation to pro-
vide people with accurate information so they can make
informed autonomous decisions about their own health.
Thus, whatever one might think about actively promoting
THR as public policy, it is per se unethical to mislead peo-
ple in order to manipulate their health behavior, even if it
is "for their own good" (Phillips CV. The affirmative ethi-
cal arguments for promoting a policy of tobacco harm
reduction. Submitted, Available at: http://www.tobacco
harmreduction.org/wpapers/010.htm). In other words,
preventing a smoker from learning about a low-risk alter-
native, even if he is about to quit entirely, is clearly unethi-
cal. Moreover, a consequentialist analysis reveals that
someone who chooses to forgo nicotine because of the
high cost of smoking but, upon learning of a low-risk way
to consume nicotine, chooses to consume low-risk nico-
tine must have concluded that the net welfare benefits of
consumption (the benefits of nicotine, net of the health
and other costs) are positive, even though the net benefits
of smoking were negative. Therefore misleading people
about the option necessarily has net negative welfare
impact (Phillips CV. The affirmative ethical arguments for
promoting a policy of tobacco harm reduction. Submit-
ted, Available at: http://www.tobaccoharmreduction.org/
wpapers/010.htm).
Nevertheless, some observers are unconcerned with these
ethical arguments. More importantly, the claim brings up
an interesting analytic question that is worth answering
even apart from the politics of THR: In terms of physical
health risks, someone who keeps smoking is clearly worse
off than someone who switches immediately, who in turn
is probably slightly worse off than someone who immedi-
ately quits entirely. But how long would someone have to
keep smoking before his health risks would have been
lower had he just switched today and used low-risk nico-Harm Reduction Journal 2009, 6:29 http://www.harmreductionjournal.com/content/6/1/29
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tine for the rest of his life? Or, equivalently, how much
time can pass while powerful interests vilify THR products
while waiting for theoretical perfect alternatives to emerge
before that delay kills as many people as using THR prod-
ucts ever could? For anyone who is primarily concerned
about maximizing health outcomes (even apart from
rights to autonomy or welfare maximization), the answer
to these questions should make it clear that THR should
immediately be embraced using currently available alter-
native products.
Analysis
It is illustrative to begin this analysis by addressing the
assertion that total social (population) risk will increase if
THR is embraced, explaining how that is insupportable,
before continuing to the new analysis of the individual
smoker who will either switch or quit.
Net effect on social risk of lowering individual risk
It is clear that lowering the risk from consuming nicotine
(or, more precisely, making people aware of the fact that
they have the option of lowering their own risk) should
result in some people using nicotine who otherwise
would not. Simple economics tells us that when the pop-
ulation learns that they can receive the benefits of nicotine
with much lower total cost (due to almost eliminating the
health risk), rational behavior causes increased consump-
tion. This means that demands like the Society for
Research on Nicotine and Tobacco's (SRNT) policy state-
ment, " [THR] should not reduce the likelihood of even-
tual cessation of tobacco use" and "should not lead to
increased population prevalence of tobacco [use]" [12]
are tantamount to saying that any step that lowers the risk
from using tobacco - whether it be creating a safer product
or finding a cure for lung cancer - is unacceptable. This is
critical to understand: Finding a cure for lung cancer
would inevitably increase the number of people who
smoke, and thus the SRNT is demanding that no such cure
be pursued. More generally, insisting that a health policy
or technology, even one that saves many lives, is only
acceptable if it does not lead to an increase in the number
of people engaging in risky activities would not only for-
bid THR, but would also prohibit condoms, sports safety
equipment, sunscreen, lifeguards, vaccines for travelers,
and trauma centers.
In fairness, those who make such statements are probably
not intentionally calling for a prohibition against lower-
ing the risks from smoking, such as by demanding that we
avoid curing cancer. They are probably just ignorant of
basic economics and how changing costs influence peo-
ple's decisions. Though there are skilled economists
involved in "tobacco control" research and advocacy, they
seem to have done little to educate or influence activism
or policy statements. The most vocal activists are clearly
unaware of the overwhelming economic evidence about
how individuals optimize consumption, or reject that evi-
dence without any basis for doing so, and thereby reject
the liberal ethics of economics-based consumer policy
that follow from it. This is not merely a matter of consid-
ering individual smokers as irrational, since it even
extends to assuming profit maximizing businesses do not
follow their best interests - e.g., they insist that prohibiting
a popular voluntary commercial choice, banning smoking
areas in pubs, does not merely result in a net health
improvement, but actually never hurts any merchant [13].
However, even though economic ignorance is a compel-
ling explanation, we cannot rule out the possibility that
many anti-tobacco extremists really mean what they say,
and actually favor maximizing the risk from using nico-
tine and otherwise intentionally lowering people's welfare
in order to make tobacco/nicotine use less appealing.
Empirical support for the economic prediction that lower-
ing risk will increase consumption (either by more people
consuming the good, or those who are consuming it using
more, or both) can be found in Sweden. Most Swedish
would-be-smokers (particularly men, but increasingly
women also) use ST instead, resulting in by far the lowest
consumption of smoked tobacco in the Western world.
The result is the expected reduction in smoking-caused
diseases, with no offsetting increase in ST-caused diseases
(which is to be expected, since no detectable level of any
disease has been shown to be caused by ST). But total
tobacco consumption in Sweden is among the highest in
Europe. Anti-tobacco extremists, therefore, consider the
Swedish experience to represent a failure, consistent with
their political goal of reducing tobacco use regardless of
the health effects. Realizing, however, that most observers
would not share that goal, they try to rationalize their
position that this public health triumph is really a failure
by trying to deny the public health gains.
Indeed, it should be recognized as a reassuring observa-
tion about people to see that when the health risk from a
consumption choice is dramatically reduced, people
rationally increase total consumption. Many readers will
probably find it odd to declare it reassuring that more
people would become nicotine users, but a single obser-
vation should be sufficient to eliminate all confusion: The
prediction that some people who would not smoke will
choose to use low-risk nicotine products is equivalent to
the more politically correct statement, "some people
choose to avoid smoking due to the high health costs even
though they would like to get the nicotine." Few would
disagree that the latter is a reassuring observation about
people's rationality.
Extending this, it is plausible that lowering the health risks
of consuming something could increase consumption to
the point that the total social risk will increase. It must be
the case that there is an improvement in total net socialHarm Reduction Journal 2009, 6:29 http://www.harmreductionjournal.com/content/6/1/29
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benefits, since the change would result from free choice of
a preferred option, and the major externalities would
likely also be positive. But health risk, considered apart
from other contributors to welfare, might increase. All
that is necessary for an increase in health risk is that the
quantity consumed goes up by enough that even with the
lower risk, the total risk (i.e., quantity consumed multi-
plied by average individual risk per unit of consumption
or, in units of people, the number of consumers multi-
plied by the average risk per consumer) is greater. Whether
this happens in a given case is an empirical point, but for
the case of smokers and some nonsmokers adopting a
low-risk nicotine product, a simple analytic reality check
shows that it is effectively impossible.
Given the estimate that switching to a low-risk alternative
reduces a smoker's risk by 99%, if only 1% of a population
switched from being continuing smokers to using THR
products, then even if the entire rest of the population
switched from no consumption to the low-risk products it
would not result in a social risk increase. (The number of
additional users necessary to make up for the risk decrease
from one switcher is easily calculated as (1-x)/x, where x =
the proportion of the risk from smoking caused by the
THR product, so since (1-.01)/.01 = 99, then for 1 smoker
who switched from smoking, there would have to be 99
non-users who took up ST to make up for it.) Even if the
alternative product was 5% as harmful as continuing to
smoke, which is difficult to imagine given the available
evidence, if 1% of the population switched (which would
represent less than 5% of all smokers in Western popula-
tions, a very modest success), the new product would have
to attract 19% of the population, roughly one-quarter of
all current non-users, to start using nicotine in the low-
risk form to result in no net gain. This would represent
total nicotine usage prevalence close to the maximum it
ever reaches, even in populations not worried about
health risks, which is presumably the total portion of the
population that benefits from using nicotine. Thus, even
a pessimistic comparative risk scenario leaves little room
for an increase in social health risk.
The argument that total population risk might increase
and therefore we should not inform people about THR -
though arithmetically absurd and based on the unethical
premise that it is acceptable to mislead people - has
proven to be a remarkably persistent rationalization for
anti-THR activists. It is so often repeated that the original
debunking of it, an article that basically just graphs the y
= (1-x)/x function and expands on the point from the pre-
vious paragraph [14], has been cited by scores of journal
articles about THR (including most of the substantive
overview articles on the topic) and hundreds of presenta-
tions and popular communications, presumably because
the later authors believed it was necessary to respond to
the claim that the article debunks. But there has not previ-
ously been a good quantitative response to the next layer
of rationalization: Even though social risk will clearly be
lower if THR is widely adopted, somewhere out there is a
hapless smoker who would have soon won his struggle to
give up nicotine to avoid all further health cost, but he
becomes doomed to failure when presented with the
information that he could use a low-risk alternative,
resulting in a net health cost.
This claim, plausible until one actually checks the num-
bers, typically takes a form like THR "may undermine
efforts leading to the healthiest outcome of all, namely,
complete tobacco abstinence". Versions of this claim are
common in statements made to the popular press by anti-
THR activists and in rhetorical documents put out by anti-
tobacco extremist organizations (though this particular
quotation actually comes from an ostensibly scientific
journal article [12]). Setting aside the inappropriate
breadth of this phrasing (it is generally accepted that
"healthiest" should incorporate psychological health, not
just longevity, and since nicotine has substantial psycho-
logical benefits, abstinence is often not healthiest), the
implicit claim is quantitative and a function of the time
periods involved. Claiming that the outcome the authors
personally prefer, abstinence, is healthiest (in the narrow
sense of maximizing life expectancy) depends on the
implicit quantitative claim that the hypothetical complete
cessation of nicotine use would have begun soon enough
that it would have resulted in less physical health risk than
consuming a low-risk alternative. (Some might claim that
such authors are merely suggesting that immediate absti-
nence would be the physically healthiest behavior, with-
out reference to what might actually happen. But this
defense is not convincing since the statements are made in
the context of policy recommendations and other practi-
cal discussions, where obviously no one would suggest
that assessing the effect of universal immediate abstinence
has any practical relevance. After all, if the authors merely
wanted to make a statement about what would be best,
without regard to what is actually possible, then making it
so that no one ever smoked in the first place would actu-
ally be best.)
Sometimes the claim is made in a form that practically
concedes that eliminating tobacco use (and often any
close substitute for it, like electronic cigarettes), rather
than improving health, is the author's primary goal (e.g.,
"The major concerns of promoting a dangerous product as
less harmful than another are that it may undermine
efforts to achieve total tobacco-product cessation" [15]).
However, such claims are typically presented in a way to
imply that readers concerned with health outcomes
should consider them to be health-based (in the previous
example, the assertion appeared under the heading, "pub-Harm Reduction Journal 2009, 6:29 http://www.harmreductionjournal.com/content/6/1/29
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lic health implications of the findings from this study").
But even authors editorializing a pro-THR position, and
thus presumably not basing their views on the anti-
tobacco extremist position, often suggest that a "down-
side" [16] of having the option to switch will cause some
people who would have quit entirely to suffer greater risk
because they switch instead. But how many potential quit-
ters actually fall into this "downside"? That is, how many
were going to quit soon enough that switching actually
represents a net increase in disease risk?
Calculation of the switch-versus-eventually-quit tradeoff
The following analysis quantifies the question about
"soon enough". Note that this calculation addresses only
the risk-risk tradeoff, ignoring any benefits of continuing
to use nicotine rather than quitting and the welfare costs
of the act of quitting. It is also limited to mortality even
though non-fatal morbidity is probably not perfectly pro-
portional to mortality risk. The latter simplification, as
well as the necessarily rough input numbers, are relatively
minor compared to the simplifications that exist (though
are seldom acknowledged) in most population health
analyses. More important, they prove to matter little,
given the clear implications of the result. This analysis
proves to be an excellent example of the value of a back-
of-the-envelope calculation as adequate response to an
unanalyzed claim: While it is often not practical to com-
plete a precise analysis of a scientific or policy claim, it is
often the case that the rough analysis that is practical is
quite adequate for present needs, and is a great improve-
ment over unquantified speculation.
For any given smoker at a particular time, who is not
already doomed to die from his smoking to date, we wish
to estimate how many days of continuing smoking causes
as much risk of death as a future lifetime of using a low
risk nicotine product. (Note: describing something as
causing someone's death is shorthand for saying that it
substantially hastened the death, and obviously not that
ever-dying was conditional on the behavior.)
Answering the question for an individual would require
determining the probability of dying from a lifetime of
THR product use, starting at the present, and the probabil-
ity of dying from future smoking as a function of how
long the smoking continues. While it would be useful to
have such a lifecycle-based model for individual deci-
sions, it is not currently possible. An individual's risk from
a lifetime of THR product use could be reasonably esti-
mated as a function of the individual's current life expect-
ancy, with possible refinement by inclusion of other
variables. But despite the extensive research on smoking
and health, there is apparently no good calculation of the
risk from a short future period of smoking, based on cur-
rent age, sex, etc. There is ample research about the bene-
fits of quitting and it clearly establishes that quitting
sooner is better, but it offers very limited information for
calculating the marginal cost of a given additional period
of smoking as a function of past smoking duration and
other individual characteristics. Thus, while comparative
observations are possible based on the demographics of
the individual in question (e.g., a very young smoker, with
a long potential period of THR product use, has more to
lose from switching rather than quitting after a particular
delay, and thus could afford a longer wait until quitting),
there is currently no realistic way to do this calculation for
individuals.
But from the public health education and policy perspec-
tive, knowing the risk-risk tradeoff on a population aver-
age basis is almost as useful, and calculating that is
possible. The population average can be viewed as com-
paring switching-now-versus-quitting-later for all smokers
acting simultaneously (which, of course, will not happen
- it is just a useful unit of analysis) or, equivalently, asking
the question for a random smoker we know nothing
about. Public health interventions, particularly the provi-
sion of information, typically affect all or random individ-
uals, making this the relevant level of analysis.
The key to the calculation is the observation that if we
assume that smoking more never cures a disease that was
caused by previous smoking, then for anyone who dies
from smoking, there will be a day, D, in his smoking his-
tory such that if he had quit entirely before that day he
would not have died from smoking, but as a result of
smoking through that day he does die from smoking.
Because we never know which day that is, and because
smoking-caused disease results from an accumulation of
insults, this observation may not be obvious to all readers.
For those who do not find this observation intuitive, a
simple proof follows.
Proof: Assume that a destined-to-be-fatal disease that
was caused by past smoking is never cured or delayed
by future smoking. Consider someone who dies from
smoking. Consider the latest day, if it exists, of smok-
ing during his life such that had he quit entirely before
that day he would not have died from smoking. Since
this is the latest such day and he did die from smoking,
if he smoked that day he would still have died from
smoking, which defines day D. The smoker's life was
finite, and thus includes a finite t days of smoking.
Had he quit just before day t, either he would have still
died from smoking (either from the disease that actu-
ally killed him or another disease also caused by
smoking) or not. If not then day t meets the definition
of D (if he had quit the day before he would not have
died, and t is necessarily the latest such day). If day t is
not D, then either he would have not died from smok-
ing if he he had only smoked through day t-2, in
which case day t-1 is D (if he had quit before that dayHarm Reduction Journal 2009, 6:29 http://www.harmreductionjournal.com/content/6/1/29
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he would not have died, and this is not true for any
later day). If t-1 is not D then a similar analysis can be
applied to t-2, and so on. Thus, by counting down
through the finite list of days, we either find some day
that is D or reach day 1 without having found D, in
which case quitting any time after day 1 would not
have stopped the death from smoking. But by hypoth-
esis the death was caused by smoking, so never starting
(quitting before day 1) would have prevented it, and
therefore day 1 is D. Therefore, D exists sometime
within the days of smoking for each individual who
dies (or is destined to die) from smoking.
The same logic proves that for every smoker who dies of
smoking there was one particular cigarette that was the
fatal point-of-no-return. The proof does not address the
fact that moving toward quitting might alter which day is
D by altering smoking intensity or starting and stopping.
It also ignores the possibility that further smoking past D
could further accelerate the death from smoking, making
the subsequent analysis conservative because it ignores
the possible longevity benefits of switching among those
already doomed to die from their smoking.
Given that everyone who dies from smoking has a D, it is
possible to estimate the increased risk of dying from
smoking for the average smoker (or all smokers) from
smoking one more day. For a typical Western population,
we can estimate the average lifetime days of smoking for
someone who dies from smoking to be about 18,000
(about 50 years). Since one of those days must be D, the
average day of smoking from someone who is destined to
die from smoking (averaged across all days of smoking
among all such individuals) has probability 1/18,000 of
being the day that doomed the smoker to die from smok-
ing. Thus, if all current smokers who are destined to die
from smoking gave up smoking tonight, some number, x,
of them would be saved from dying from smoking, but if
instead they gave up smoking tomorrow night, only x
minus 1/18,000th of that population would be saved.
Notice one immediate observation based on this that is
apparently not obvious to many smokers and people who
give advice on these matters: Quitting someday is not suffi-
cient - it is possible to quit too late and there is no way to
know in advance which day is one day too late.
Estimates for Western populations of the fraction of cur-
rent smokers whose deaths will be caused by smoking
range from 1/4 to 1/2, so roughly one death from smok-
ing is caused by each 50,000 days of smoking. The best
available estimate is that the average risk of dying from
THR product use is about 1% that from smoking. Follow-
ing the above logic, this represents 5×106 days of use per
death caused. Since the ratio of the risk from THR product
use compared to smoking enters the calculation linearly,
readers who believe the ratio is really 2% or 3% can adjust
the final estimates upward by a factor of 2 or 3. (Readers
who believe the ratio is much more than that should take
a closer look at the scientific evidence.) Assume that the
total risk from THR product use is the same whether it is a
lifetime of exclusive THR product use or switching to THR
products after some period of smoking. Note that this is a
conservative assumption, since any smoker who is already
doomed to die from smoking experiences no increase in
the chance of dying from nicotine use by using a THR
product. Moreover, it seems fairly likely that if THR prod-
uct use causes any negative health impacts other than the
minor effects of nicotine itself, then they are not exactly
the same as those from smoking, and so the additive
health effect of THR product use on top of smoking would
probably be less than the additive effect of a longer term
of THR product use.
We can estimate that if smokers who are going to eventu-
ally cause themselves to die from smoking will smoke an
average of 18,000 days, then the average such current
smoker has about 9,000 days of smoking ahead of him.
(This is would be exactly true if we were in steady-state
with respect to smoking and if smokers with fewer days of
smoking ahead of them were not more likely to already be
doomed. Failures of these assumptions will tend toward
canceling out, and the net error seems to be within the
limited precision built into the calculation.) Thus, using
the conservative simplification above, if the average such
smoker switches immediately, he has a 9,000/5×106 ≈ 1/
600 chance of dying from ST use. Comparing this to his
extra probability of dying from smoking by waiting longer
to completely quit, at 1/18,000 chance of causing death
per day, shows that this is the equivalent of delaying quit-
ting by about one month. Thus, on average, this smoker
only endures greater total risk from using a THR product
for the rest of his life if he were going to become abstinent
in less than a month.
Note that the "all smokers" or "randomly selected individ-
ual" condition is crucial here since, for example, a partic-
ular smoker who is young and therefore has not yet
smoked much can probably get away with smoking years
more before being doomed, but has many more days of
potential THR product use ahead of him, might not reach
risk parity for several months. Conversely, there are older
demographic groups, possibly identifiable, who may not
yet be doomed but are much more likely than average to
be close, for whom a single additional day of smoking
poses greater risk than a future lifetime of THR product
use.
Discussion
While it is logically possible that lowering the risk from an
exposure could increase population risk, the (1-x)/x calcu-
lation shows this is not plausible for THR. The suggestionHarm Reduction Journal 2009, 6:29 http://www.harmreductionjournal.com/content/6/1/29
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that, despite the lower population risk, many individuals
might still face greater risk is also logically possible, but
the calculation presented here shows that this is not a sub-
stantial practical worry.
On average, someone who would die from smoking who
is going to take more than a month to quit entirely (or will
experience relapses that will have a similar health impact
- probably roughly a total of one month worth of days)
will have less total health risk by switching immediately,
even if he never quits the alternative product. The typical
pattern of even dedicated quitters, starting and stopping
smoking for a year or two, will cause much more risk than
switching to a low-risk alternative. Moreover, even an
average smoker who was going to successfully quit after
only a week or two more will suffer only a tiny net
increase in physical health risk from switching now, a
change so trivial compared to the net benefits of switching
for smokers who will not quit for years or ever that it is
clearly inconsequential.
The practical implications of this analysis do not change
based on plausible variations in the input parameters,
including the risk from using ST. Even if we use a com-
pletely implausible high risk from ST use, say that it causes
10% of the risk of smoking, then if an average smoker
would have taken ten months to quit entirely, he would
have had lower risk had he switched immediately. The
break-even might be as low as about half a year - recall the
conservative assumption built into the calculation. Thus,
even discovering that ST use is an order of magnitude
worse than the ample current evidence suggests would not
fundamentally change the implications of the analysis.
Since this analysis is based entirely on mortality risk, it
ignores other contributions to welfare. The reason that
current smokers have not already quit, in spite of the
health benefits of doing so, is that it would have resulted
in substantial costs to them and, similarly, whenever a
smoker chooses to switch it implies that there is a net wel-
fare benefit (compared to either smoking or abstinence)
to using the alternative product. This welfare gain from
switching rather than quitting probably dwarfs the welfare
implications of the mortality risk from low-risk products,
though quantifying that is beyond the present scope.
Finally, it is worth noting that someone who switches
from smoking to a low-risk alternative still has the option
of quitting entirely, lowering his risk slightly more still.
Indeed, there is reason to believe that eventually quitting
alternative products is easier. This means that even the
young smokers who might have been better off with sev-
eral more months of smoking rather than a lifetime of
THR product use stand a good chance of quitting entirely
anyway (if they decide that the benefits of consumption
are outweighed by the benefits of quitting), further favor-
ing the option of switching now. Even those smokers who
cannot afford another day of smoking but fortunately
switch just in time (who are likely from older demograph-
ics that are the primary target for THR) could then survive
long enough to quit nicotine entirely.
Many of the claims about health risk made to try to dis-
courage the adoption of THR have been proven to be out-
and-out false. This includes the "total social health risk
will increase" claim. The present analysis does not relegate
the "some people would be stopped from quitting entirely
and thus have worse health outcomes" claim to universal
falsehood - it will still inevitably be true for a very few
individuals. But this is common in public health interven-
tions, from automobile safety equipment to vaccines - the
net social effects are overwhelmingly beneficial, though
some people (who cannot be identified ex ante, and often
not even ex post) suffer net harm rather than benefit. The
analysis shows that only a tiny portion of all future quit-
ters will be quitting soon enough that they would have
higher expected risk by switching immediately. Moreover,
the net increase in expected risk even for those individuals
would be extremely small, and the net welfare effects
would still be positive. Clearly, then, the claim does not
represent a sufficient concern to override the huge net
expected social benefit, to say nothing of the ethical
requirement that smokers be informed about their
options. The claim is thus relegated to being a distraction
from rational and honest discourse on the subject, not a
contribution to it.
This calculation emphasizes the cost of delaying the adop-
tion of THR at the individual level also: Those of us who
promote THR are familiar with smokers who, upon learn-
ing about THR, insist that they do not need to consider
that option because they will eventually be exercising the
"perfect" option of quitting anyway. But many such indi-
viduals never quit, and almost none quit in time for it to
be a healthier choice. Similarly, each additional month
that anti-THR activism keeps a potential switcher from
learning about THR is more likely to kill him than is a life-
time of using ST or another low-risk nicotine product. To
put it bluntly, anti-THR activism and disinformation do
far more damage to public health than smokeless tobacco,
electronic cigarettes, or other THR products ever could.
Since THR can be self-tailored and requires no clinical or
government intervention, it does not matter that there
may be smokers for whom no low risk product is an ade-
quate substitute or that there is no political will to actively
endorse it. THR can be adopted by individuals who do
find an acceptable substitute, and likely will be widely
adopted if smokers were simply given accurate informa-
tion. The usual explanation for the lack of such informa-
tion is that anti-tobacco extremists promulgate
disinformation it and then even the opinion leaders whoHarm Reduction Journal 2009, 6:29 http://www.harmreductionjournal.com/content/6/1/29
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are genuinely concerned about public health repeat the
inaccurate claims because they have been misled. But an
alternative explanation is misplaced optimism on the part
of the public health leaders: That is, many may not be mis-
led by the disinformation about THR, but may genuinely
believe that most smokers will successfully quit using nic-
otine very soon or that a perfect new anti-smoking
method, policy, or product will be developed and cause
everyone to quit soon, reducing their risks more than THR
would. The present analysis shows just how overly-opti-
mistic that belief needs to be in order to justify the failure
to immediately promote THR using current technology.
Whatever the explanation for it, the present analysis
shows that anti-THR activism is deadly. Hiding THR from
smokers, waiting for them to decide to quit entirely or
waiting for a new anti-smoking magic bullet, causes the
deaths of more smokers every month than a lifetime using
low-risk nicotine products ever could.
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